Futura Medical has made key progress in its sexual health portfolio by appointing Market Performance Group as its new US commercial partner, replacing Haleon. This move aims to revitalize growth in the large US erectile dysfunction market. The company also reported positive trial results for its Eroxon Intense gel and WSD4000 female sexual health gel, with regulatory approvals pending. Despite improved revenues and reduced losses in H1 2026, Futura faces cash constraints and is exploring funding options to sustain operations beyond October.
Energy Fuels CEO Bhappu sold 14,375 shares of the company to cover tax withholding obligations. This transaction is a routine financial move related to tax compliance and does not indicate a change in company leadership or strategy. Investors should ...
Bunzl PLC has announced a £500 million share buyback programme over the next 12 months to return excess cash to shareholders while maintaining capacity for acquisitions. The initial phase, running until December 22, 2026, will repurchase up to 32.4 m...
Connecting Excellence Group Plc has agreed to acquire two UK recruitment companies specializing in construction and engineering, with combined revenue of £1.79 million and EBITDA of £431,000. The deal involves an initial net cash outflow of £150,000,...
Bradda Head Lithium Ltd announced surface assay results showing lithium oxide grades up to 3.9% from its Whistlejacket project in Arizona. This concludes the 2026 rock-chip sampling program, with 19 of 41 samples exceeding 0.50% lithium oxide and low...
Inturai Ventures Corp. has finalized its acquisition of DomeCommand, an AI-driven command-and-control platform for autonomous drone swarms. The deal includes intellectual property rights and a royalty-free license for the underlying software, with a ...
